ChemPartner is a science-based, technology-driven global Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) headquartered in Shanghai, China. The company offers a comprehensive range of services across the pharmaceutical value chain, from drug discovery through to commercial manufacturing. With over 20 years of experience, ChemPartner has evolved from a chemistry-focused service provider to a full-service partner for biopharma companies worldwide.

Core Services:

Discovery Chemistry: Providing synthetic, medicinal, peptide, carbohydrate, and nucleic acid chemistry, along with computer-aided drug design and analytical services.

Biology and Pharmacology: Offering in vitro biology, cell biology, and disease models in oncology, immunology, inflammation, immuno-oncology, and neuroscience.

DMPK and Exploratory Toxicology: Conducting ADME studies, pharmacokinetics, exploratory toxicology, bioanalysis, and regulatory support.

Biologics Discovery: Specialising in antibody discovery, protein science, and biophysical characterisation.

Biologics CMC and Manufacturing: Providing cell line development, process development, formulation, cGMP manufacturing, and analytical testing.

Global Presence and Expansion:

ChemPartner operates globally, with facilities and representatives in China, Europe, and the United States. The company recently announced the opening of its Boston Center of Excellence in Watertown, Massachusetts, set to commence operations on 10 September 2025. This facility will offer discovery and preclinical services to biopharma clients in North America and beyond.

ChemPartner is committed to providing high-quality, cost-effective R&D services to the biopharmaceutical industry. With a broad portfolio of services and a global presence, ChemPartner is well-positioned to support clients across the drug discovery and development pipeline.